Committee for Orphan Medicinal Products (COMP) Jan 2010 meeting: Orphan medicinal product designation.

At its meeting of 5-6 Jan 2010, the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) adopted four positive opinions recommending the following medicines for designation as orphan medicinal products to the European Commission: For the following medicine the review began on 9 Oct 2009 with an active review time of 90 days: Taliglucerase alfa for treatment of Gaucher disease, Protalix BV. For the following medicines the review began on 6 Nov 2009 with an active review time of 62 days: (1S, 2S, 3R, …